London and Boston-based Outpost Bio has secured $3.5 million in pre-seed financing to build a platform that links experimental microbiology with machine learning models of the human microbiome.

The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and several strategic family offices and angel investors. The pre-seed capital will be allocated toward platform buildout, dataset expansion, and establishing partnerships with pharmaceutical and consumer-sector R&D teams.

Outpost Bio is focused on the human microbiome, the complex ecosystem of bacteria, fungi, and other microorganisms that influence drug metabolism, nutrient processing, and host physiology—what the company calls biology’s “hidden majority.” 

Outpost states its objective is to make these microbial ecosystems “computable” by pairing automated wet-lab experimentation with machine learning in a closed-loop system. Beyond building predictive models of how interventions alter microbial communities, Outpost says it intends to contribute foundational datasets and models to the broader scientific community and is actively seeking collaborators with well-characterized pre- and post-intervention microbiome datasets. 

While interest in microbiome research has grown across pharmaceutical, nutrition, and consumer health sectors, predictive modelling remains limited by fragmented workflows and high-dimensional biological data. 

Human microbiology presents technical challenges because microbial communities are dynamic, context-dependent, and shaped by nonlinear interactions among species and host factors. Data is often sparse, heterogeneous, and difficult to benchmark against clear biological ground truth. 

Outpost Bio’s aim is to turn these fragmented, high-dimensional microbiome data into computational infrastructure that can support more predictive and personalized approaches to medicine.